Bicara Therapeutics Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
65.9M
on 2026-06-30, from 54.4M on 2024-09-30 10-Q ↗
a raise that quarter, at its price
$150.0M
TD Securities (USA), agreement of 2025-10-03. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-11 is not read yet.
Cash
14.8 quarters
$497.3M on 2026-06-30 ÷ $33.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-02-26 | Public offering incl. 2.20M pre-funded | 9,375,000 | $16.00 | $150.0M | 424B5 ↗ |
| 2024-09-12 | Public offering | 17,500,000 | $18.00 | not read | 424B4 ↗ |